Results 11 to 20 of about 128,118 (293)
Haematologica, 2015 The prognosis of older patients with acute myelogenous leukemia is generally poor. The interleukin-3 receptor α-chain (CD123) is highly expressed on the surface of acute leukemia cells compared with normal hematopoietic stem cells.
Erwin M. Lee +12 more
doaj +2 more sources
Nature Communications, 2021 Identifying novel drug targets to overcome resistance to tyrosine kinase inhibitors (TKIs) and eradicating leukemia stem/progenitor cells are required for the treatment of chronic myelogenous leukemia (CML).
Hu Lei +21 more
semanticscholar +1 more source
Cancer, 2020 CXCR4 mediates the retention and survival of acute myelogenous leukemia blasts in bone marrow and contributes to their resistance to chemotherapy. The authors evaluated a combination of the high‐affinity CXCR4 antagonist BL‐8040 with high‐dose cytarabine
G. Borthakur +29 more
semanticscholar +1 more source
Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options [PDF]
, 2018 The onset of global epigenetic changes in chromatin that drive tumor proliferation and heterogeneity is a hallmark of many forms cancer. Identifying the epigenetic mechanisms that govern these changes and developing therapeutic approaches to modulate ...
Koschmieder, Steffen, Vetrie, David
core +1 more source
Assessment of Psychological Problems for Patients with Acute Myelogenous Leukemia
Kufa Journal for Nursing Sciences, 2015 Objective: To assess the psychological problems in patients with acute myelogenous leukemia, and to find out the relationship between socio-demographic characteristics such as (age, sex, marital status, educational level, and occupation) and ...
Kareem R. Sachitt
doaj +3 more sources
Physiologically Based Pharmacokinetic Modeling in Patients With Hepatic Impairment: Are Changes in Bosutinib Exposure Profiles Driven by Altered Absorption or Distribution? [PDF]
CPT Pharmacometrics Syst PharmacolABSTRACT Bosutinib is an orally available Src/Abl tyrosine kinase inhibitor and has been approved for the treatment of patients with Ph + chronic myelogenous leukemia. Bosutinib is a substrate of P‐glycoprotein (P‐gp) in vitro and is predominantly metabolized by CYP3A4 in humans with minimal urinary excretion.
Muto C, Jones HM, Yamazaki S.
europepmc +2 more sources
CHRONIC MYELOGENOUS LEUKAEMIA [PDF]
British Journal of Haematology, 2000 In the last decade, improvements in both non-transplant and transplant therapy have extended the lives of patients with CML, particularly those in chronic phase. The future will probably bring a greater understanding of molecular leukaemogenesis and options for treating CML. Non-transplant therapies in development include novel agents and
openaire +2 more sources
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells [PDF]
, 2016 Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at risk for relapse, and additional approaches to deplete CML LSC are needed to enhance the ...
Agarwal, Puneet +9 more
core +1 more source
Revista Brasileira de Hematologia e Hemoterapia, 2012 BACKGROUND: Chronic myeloid leukemia is a neoplasm characterized by clonal expansion of hematopoietic progenitor cells resulting from the (9:22)(q34,11) translocation.
Maria Juracy Petrola +6 more
doaj +1 more source
The chronic myeloid leukemia stem cell: stemming the tide of persistence [PDF]
, 2017 Chronic myeloid leukaemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a haemopoietic stem cell (HSC), transforming it into a leukaemic stem cell (LSC) that self-renews, proliferates and differentiates to give rise to a ...
Holyoake, Tessa L., Vetrie, David
core +1 more source